IFCAH-ESPE Grant supports academic researchers studying congenital adrenal hyperplasia mechanisms, complications and new therapies to improve treatment and patients’ quality of life.
Funder: European Society for Paediatric Endocrinology
Due Dates: January 15, 2027 (LOI) | April 30, 2027 (Full application; exact day unconfirmed)
Funding Amounts: Up to €150,000 per project for up to three years; €350,000 available across projects
Summary: Supports academic research on congenital adrenal hyperplasia mechanisms, complications and new therapies to improve patients’ quality of life.
Key Information: Applicants need an M.D., Ph.D. or equivalent and a faculty position or equivalent at an academic institution.
The IFCAH-ESPE Grant supports academic research to improve treatment and quality of life for people with congenital adrenal hyperplasia (CAH). IFCAH, founded in 2010 by parents of children affected by CAH, runs the annual call with the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). It encourages original research that advances understanding of the disease or enables better therapeutic approaches.
Priorities include CAH pathophysiology, adrenal development, differentiation and homeostasis, and prevention, diagnosis and treatment of natural or treatment-induced complications. Relevant complications span foetal development, growth, puberty, metabolism, cardiovascular health, fertility, bone density, immunity, infection and neurocognition. The programme also supports new therapeutic targets and protocols, pharmacotherapy, improved treatment monitoring, and gene or cellular therapy models.